Aripiprazole Found to Have Fewer Side Effects in Teens With First-Episode Psychosis

Young people with first-episode psychosis (FEP) who are treated with extended-release quetiapine gain more weight and experience worse metabolic effects —including increased lipids, insulin, triglycerides, and total cholesterol—than patients treated with aripiprazole, according to areport in theJournal of the Academy of Child and Adolescent Psychiatry.“These differences emerged early, are clinically relevant, and should inform treatment choice for youths with early onset psychosis,” especially since studies have shown the two medications are equally effective in treating symptoms, say Karsten Gjessing Jensen, M.D., Ph.D., of the University of Copenhagen and colleagues.The researchers analyzed data on 113 youth aged 12 to 17 with FEP who were randomized to 12 weeks of extended-release quetiapine (quetiapine-ER) or aripiprazole as part of the Tolerability and Efficacy of Antipsychotics trial. The trial was conducted from June 2010 to April 2014 in seven university child and adolescent psychiatry departments across Denmark.The primary outcome was change in body weight; secondary outcomes were changes in body mass index (BMI), waist circumference, blood pressure, heart rate, and lipid and glucose metabolism measures. Patients were assessed and blood samples taken at 4 and 12 weeks. The researchers also examined family history for factors that might predict how youth would respond on weight and metabolic measures.Treatment with quetiapine-ER was associated ...
Source: Psychiatr News - Category: Psychiatry Tags: aripiprazole BMI cholesterol JAACAP metabolic disease metabolic syndrome quetiapine teens and sga antipsychotics weight gain Source Type: research

Related Links:

Publication date: Available online 13 January 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Rajvir BhalwarAbstractMetabolic Syndrome (MetS) is a clustering of specific risk factors, namely, central obesity, raised blood pressure, impaired fasting glucose, raised triglycerides, and low levels of high-density lipoprotein-cholesterol (HDL-C). This constellation is triggered by insulin resistance and its resultant hyperinsulinemia. The two most important and universally agreed causes of insulin resistance are increased body fat (particularly central obesity) and physical inactivity. Other causes include certain gene...
Source: Medical Journal Armed Forces India - Category: General Medicine Source Type: research
ska M Abstract In the study, 305 patients of both genders were enrolled and divided into three groups: obese (BMI> 30 kg/m2), patients who were diagnosed type 2 diabetes mellitus (T2DM), and control, normal weight healthy volunteers. At least one of ten different phthalate metabolites was determined in the urine samples of 49.84% all enrolled participants. In the obese subgroup, the sum of all urinary phthalate metabolites was positively associated with TG levels (p = 0.031) together with derived TC/HDL and TG/HDL ratios (p = 0.023 and 0.015), respectively. Urinary MEP concentration was positively correlated wi...
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Tags: Environ Sci Pollut Res Int Source Type: research
Albiflorin (AF) is a small molecule (MW 481) isolated from Paeoniae radix, a plant used as a remedy for various conditions with pathogenesis shared by metabolic diseases. Reported here is our characterization of its therapeutic profiles in three mouse models with distinctive pathological features of metabolic syndrome (MetS). Our results firstly showed that AF alleviated high fat (HF) induced obesity and associated glucose intolerance, suggesting its therapeutic efficacy for MetS. In the type 2 diabetes (T2D) model induced by a combination of HF and low doses of streptozotocin, AF lowered hyperglycaemia and improved insuli...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: Gao RY, Hsu BG, Wu DA, Hou JS, Chen MC Abstract Background: Fibroblast growth factor 21 (FGF21) acts as a potent metabolic regulator. Serum FGF21 levels were significantly higher in obesity and type 2 diabetes mellitus (T2DM) populations. The aim of this study was to evaluate the relationship between serum FGF21 levels and metabolic syndrome (MetS) in T2DM patients. Methods: Fasting blood samples were obtained from 126 T2DM patients. MetS and its components were defined according to the diagnostic criteria from the International Diabetes Federation. Serum FGF21 concentrations were measured using a comm...
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
This study investigated the therapeutic outcomes of LDJB-SG and predictors of type 2 diabetes (T2D) remission in Chinese patients with a body mass index (BMI) of 20 to 32.5 kg/m2. SETTING: A university hospital. METHODS: This retrospective study included 28 T2D patients with a BMI of 20 to 32.5 kg/m2 who underwent LDJB-SG. T2DM remission, weight loss, postoperative nutrition status, and complications at 1- and 3-year follow-up were assessed. Remission of T2DM was defined as a fasting blood glucose
Source: Surgery for Obesity and Related Diseases : official journal of the American Society for Bariatric Surgery - Category: Surgery Authors: Tags: Surg Obes Relat Dis Source Type: research
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
Several studies highlight that testosterone deficiency is associated and predicts increased risk of developing metabolic disorders, and, that it is highly prevalent in obesity, metabolic syndrome and type-2 diabetes mellitus. Models of gonadotropin releasing hormone deficiency and androgen deprivation in patients with prostate cancer suggest that hypogonadotropic hypogonadism might contribute to onset or further worsen metabolic conditions by means of increased fat mass and insulin resistance. Nevertheless, in functional hypogonadism, such as late onset hypogonadism, the relationship between hypogonadotropic hypogonadism a...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
In conclusion, we show here that sEVs are responsible for mediating paracrine senescence and speculate that they could be involved in inducing bystander senescence during therapy-induced senescence or aging. In fact, when compared to soluble factors, sEVs have different biophysical and biochemical properties as they have a longer lifespan than do soluble factors and they are more resistant to protease degradation. The idea that blocking sEV secretion could be a potential therapeutic approach to alleviate senescence "spreading" during chemotherapy-induced senescence or in aging tissues presents itself as a very at...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 13 July 2019Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Nadia Hamjane, Fatiha Benyahya, Mohcine Bennani Mechita, Naima Ghailani Nourouti, Amina BarakatAbstractAimThe aim of this work was to study overweight and obesity and their associated complications according to obesity indicators in a population of Tangier.MethodsA total of 480 overweight and obese patients were included in this study, referred to hospital Duc Tovar of Tangier during a period of 12 months. The collection of data has been done through a questionnaire which included anthropometric...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: Available online 17 June 2019Source: Genes &DiseasesAuthor(s): Fateme Sadat Eshaghi, Hamideh Ghazizadeh, Sakine Kazami Nooreini, Ameneh Timar, Habibollah Esmaeily, Mehrane Mehramiz, Amir Avan, Majid Ghayour-MobarhanAbstractMetabolic syndrome (MetS) is a clustering of metabolic abnormalities that is associated with increased risk of developing cardiovascular disease and type 2 diabetes. There is growing body of data showing the associations of genetic variants of the genes involved in the PI3K/AKT/mTOR pathway with diabetes and obesity. We aimed to investigate the association between MetS and its compo...
Source: Genes and Diseases - Category: Genetics & Stem Cells Source Type: research
More News: Abilify | Academies | Cardiology | Children | Cholesterol | Denmark Health | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Health Management | Heart | Insulin | Metabolic Syndrome | Obesity | Psychiatry | Seroquel | Study